Report - La terapia del paziente EGFR mutato - AIOM · 3rd generation EGFR-TKIs targeting T790M Drug Company Clinical Stage ORR DCR PFS (month) AZD9291 Astra Zeneca Phase III (Approved) 61%

Select PornographicDefamatoryIllegal/UnlawfulSpamOther Terms Of Service ViolationFile a copyright complaint

Please pass captcha verification before submit form